Introducing the NULISAqpcr™ AD 5-plex Assay
FREMONT, Calif. — Alamar Biosciences, Inc. is excited to share the launch of the revolutionary Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This advanced tool enables the simultaneous measurement of five significant blood-based biomarkers that are essential for Alzheimer's research. These biomarkers include brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (A?42), glial fibrillary acidic protein (GFAP), and APOE4 carrier status, all analyzed from a single blood or plasma sample.
Revolutionizing Alzheimer's Disease Research
The NULISAqpcr AD 5-plex Assay consolidates these key biomarkers into a single multiplexed format, offering superior sensitivity, specificity, and user-friendliness. By integrating these critical components, researchers can effectively monitor amyloid and tau pathology, measure neurodegeneration, and assess inflammation levels—all while determining the APOE4 carrier status, which is recognized as the most significant genetic risk factor for Alzheimer's disease.
A Comprehensive Biomarker Solution
This assay simplifies testing processes that traditionally required multiple single-plex assays, thereby easing the burden on researchers and clinicians. It facilitates a thorough understanding of Alzheimer's pathology while enabling broader applicability to other neurodegenerative and cognitive disorders. The significance of having such a powerful tool cannot be overstated and revolutionizes the way we can approach research in this field.
Expert Insights on the Launch
Dr. Yuling Luo, founder and CEO of Alamar, stated, "The launch of the NULISAqpcr AD 5-plex Assay signifies a pivotal moment in the delivery of precision proteomics solutions for neurodegenerative diseases. By integrating these essential protein markers into a single, streamlined assay, we are equipping the neuroscience community with the tools necessary for improved screening, early detection, and precise diagnoses for Alzheimer's disease."
Transforming Research with Blood-Based Biomarkers
Dr. Steven Williams, Chief Scientific Officer at Alamar, expressed, "Blood-based biomarkers are reshaping Alzheimer's research by providing a more accurate, cost-effective, and accessible method for early diagnosis and determining therapy eligibility. Traditional assays only measure these biomarkers one at a time, necessitating multiple tests to attain a comprehensive understanding of the disease. With our NULISA™ approach, researchers can now assess multiple proteins related to Alzheimer's in a blood sample, each providing critical insights into the underlying disease mechanisms."
Collaboration and Future Directions
Alamar is committed to partnering with researchers, clinicians, and the industry to unlock the full potential of precision proteomics and enhance clinical outcomes for those affected by Alzheimer's and other neurodegenerative conditions. The NULISAqpcr AD 5-plex Assay is now available through Alamar's Technology Access Program, thus fostering collaboration in advancing research.
For more detailed information on the NULISAqpcr AD 5-plex Assay and Alamar's comprehensive suite of precision proteomic solutions, visit Alamar’s official site.
About Alamar Biosciences, Inc.
Alamar Biosciences is a leading life sciences company dedicated to fostering precision proteomics that facilitates the earliest detection of diseases. Utilizing proprietary NULISA™ technology and the ARGO™ HT System, Alamar’s platform delivers ultra-high sensitivity and addresses the limitations of existing technologies to advance precision medicine.
Frequently Asked Questions
What is the NULISAqpcr AD 5-plex Assay?
The NULISAqpcr AD 5-plex Assay is a diagnostic tool that measures key blood-based biomarkers associated with Alzheimer's disease from a single sample.
What biomarkers does the assay measure?
The assay measures BD-pTau217, NfL, A?42, GFAP, and APOE4 carrier status.
How does this assay impact Alzheimer's research?
It provides a more efficient method for monitoring the disease by combining essential biomarkers into a single test, thereby facilitating early detection and diagnosis.
Who developed the NULISAqpcr AD 5-plex Assay?
It was developed by Alamar Biosciences, a leader in precision proteomics.
Where can I find more information about this assay?
Information is available on Alamar Biosciences' official website, where their innovation processes and products are detailed.
